naltrexone and Uterine Cervical Neoplasms

naltrexone has been researched along with Uterine Cervical Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Adachi, N; Hiraoka, M; Ishida, M; Ishiguro, T; Itoga, T; Onishi, H; Sugano, K; Yaguchi, A1
Chen, H; Gao, S; Hu, F; Liu, N; Ma, M; Qu, N; Shan, F; Wang, R1

Other Studies

2 other study(ies) available for naltrexone and Uterine Cervical Neoplasms

ArticleYear
Naldemedine-induced opioid withdrawal syndrome with severe psychiatric symptoms in an advanced cervical cancer patient without brain metastasis.
    Palliative & supportive care, 2022, Volume: 20, Issue:3

    Topics: Adult; Analgesics, Opioid; Brain Neoplasms; Constipation; Female; Humans; Naltrexone; Narcotic Antagonists; Uterine Cervical Neoplasms

2022
Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo.
    International immunopharmacology, 2020, Volume: 86

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytokines; Epithelial-Mesenchymal Transition; Female; Gene Knockdown Techniques; Humans; Macrophage Activation; Mice, Inbred BALB C; Mice, Nude; Naltrexone; Receptors, Opioid; Snail Family Transcription Factors; Tumor-Associated Macrophages; Uterine Cervical Neoplasms; Vimentin; Xenograft Model Antitumor Assays

2020